文献速递心脑血管急症消化、代谢与肾脏急症

普伐他汀与常规治疗对老年人一级心血管预防的影响:ALLHAT-LLT随机临床试验

Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2017-01-01
一句话结论在65岁及以上无动脉粥样硬化性心血管疾病的高血压患者中,普伐他汀40 mg/d用于一级预防未发现获益,75岁及以上者全因死亡风险呈非显著升高方向(HR 1.34,95%CI 0.98-1.84)。

该研究为ALLHAT-LLT试验的事后二次数据分析,纳入2867例65岁及以上、无动脉粥样硬化性心血管疾病证据的流动高血压成人,随机接受普伐他汀钠40 mg/d或常规治疗。主要终点为全因死亡。结果显示,普伐他汀组与常规治疗组全因死亡风险无显著差异(65岁及以上HR 1.18,95%CI 0.97-1.42,P=0.09;65-74岁HR 1.08,95%CI 0.85-1.37,P=0.55;75岁及以上HR 1.34,95%CI 0.98-1.84,P=0.07),冠心病事件率组间无显著差异。作者结论认为,对中度高脂血症合并高血压的老年人,普伐他汀一级预防未发现获益,75岁及以上者全因死亡呈非显著升高方向。

要点

  • 65岁及以上无动脉粥样硬化性心血管疾病的高血压成人,普伐他汀40 mg/d一级预防未降低全因死亡(HR 1.18,95%CI 0.97-1.42,P=0.09)。
  • 75岁及以上亚组,普伐他汀组全因死亡HR 1.34(95%CI 0.98-1.84,P=0.07),为非显著升高方向。
  • 65-74岁亚组全因死亡HR 1.08(95%CI 0.85-1.37,P=0.55),组间无显著差异。
  • 冠心病事件率在普伐他汀组与常规治疗组间无显著差异。
  • 多变量回归结果仍无显著差异,治疗分组与年龄无显著交互作用。

适用人群与场景

  • 65岁及以上、无动脉粥样硬化性心血管疾病证据的流动高血压成人,来自ALLHAT-LLT试验。
  • 纳入年龄分层为65-74岁和75岁及以上两个亚组。

处置流程与药物剂量

  • 普伐他汀钠40 mg/d口服,与常规治疗比较;常规治疗组未强制使用他汀。
  • 第6年时,普伐他汀组253例中42例(16.6%)未服用任何他汀;常规治疗组71.0%未服用任何他汀。

研究设计与关键结果

  • 研究类型:ALLHAT-LLT随机临床试验的事后二次数据分析;样本量2867例;513个临床中心;1994年2月至2002年3月。
  • 普伐他汀组1467例(平均年龄71.3岁,SD 5.2;女性48.0%,n=704),常规治疗组1400例(平均年龄71.2岁,SD 5.2;女性50.8%,n=711)。
  • 基线平均LDL-C:普伐他汀组147.7 mg/dL(SD 19.8),常规治疗组147.6 mg/dL(SD 19.4);第6年平均LDL-C:普伐他汀组109.1 mg/dL(SD 35.4),常规治疗组128.8 mg/dL(SD 27.5)。
  • 主要终点全因死亡:65岁及以上普伐他汀组vs常规治疗组HR 1.18(95%CI 0.97-1.42,P=0.09);65-74岁HR 1.08(95%CI 0.85-1.37,P=0.55);75岁及以上HR 1.34(95%CI 0.98-1.84,P=0.07)。
  • 冠心病事件率组间无显著差异;多变量回归结果仍无显著差异,治疗分组与年龄无显著交互作用。

证据类型、等级与局限

  • 证据类型:随机临床试验(ALLHAT-LLT)的事后二次数据分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:对中度高脂血症合并高血压的老年人,普伐他汀用于一级预防未发现获益;75岁及以上成人中观察到全因死亡非显著升高方向。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: While statin therapy for primary cardiovascular prevention has been associated with reductions in cardiovascular morbidity, the effect on all-cause mortality has been variable. There is little evidence to guide the use of statins for primary prevention in adults 75 years and older.

OBJECTIVES: To examine statin treatment among adults aged 65 to 74 years and 75 years and older when used for primary prevention in the Lipid-Lowering Trial (LLT) component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

DESIGN, SETTING, AND PARTICIPANTS: Post hoc secondary data analyses were conducted of participants 65 years and older without evidence of atherosclerotic cardiovascular disease; 2867 ambulatory adults with hypertension and without baseline atherosclerotic cardiovascular disease were included. The ALLHAT-LLT was conducted from February 1994 to March 2002 at 513 clinical sites.

INTERVENTIONS: Pravastatin sodium (40 mg/d) vs usual care (UC).

MAIN OUTCOMES AND MEASURES: The primary outcome in the ALLHAT-LLT was all-cause mortality. Secondary outcomes included cause-specific mortality and nonfatal myocardial infarction or fatal coronary heart disease combined (coronary heart disease events).

RESULTS: There were 1467 participants (mean [SD] age, 71.3 [5.2] years) in the pravastatin group (48.0% [n = 704] female) and 1400 participants (mean [SD] age, 71.2 [5.2] years) in the UC group (50.8% [n = 711] female). The baseline mean (SD) low-density lipoprotein cholesterol levels were 147.7 (19.8) mg/dL in the pravastatin group and 147.6 (19.4) mg/dL in the UC group; by year 6, the mean (SD) low-density lipoprotein cholesterol levels were 109.1 (35.4) mg/dL in the pravastatin group and 128.8 (27.5) mg/dL in the UC group. At year 6, of the participants assigned to pravastatin, 42 of 253 (16.6%) were not taking any statin; 71.0% in the UC group were not taking any statin. The hazard ratios for all-cause mortality in the pravastatin group vs the UC group were 1.18 (95% CI, 0.97-1.42; P = .09) for all adults 65 years and older, 1.08 (95% CI, 0.85-1.37; P = .55) for adults aged 65 to 74 years, and 1.34 (95% CI, 0.98-1.84; P = .07) for adults 75 years and older. Coronary heart disease event rates were not significantly different among the groups. In multivariable regression, the results remained nonsignificant, and there was no significant interaction between treatment group and age.

CONCLUSIONS AND RELEVANCE: No benefit was found when pravastatin was given for primary prevention to older adults with moderate hyperlipidemia and hypertension, and a nonsignificant direction toward increased all-cause mortality with pravastatin was observed among adults 75 years and older.

TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00000542.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Han BH, Sutin D, Williamson JD, et al. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. JAMA Intern Med. 2017. PMID: 28531241. doi:10.1001/jamainternmed.2017.1442

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。